Long-term Antiplatelet Therapy (Aspirin)
Treatment for Ischemic Stroke
Typical Dosage: 75-100 mg daily
Effectiveness
75%
Safety Score
80%
Clinical Trials
5
Participants
200K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
75-100 mg daily
Time to Effect
months to years
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
40(Treat 40 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
300(Treat 300 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$50
Side Effect Mgmt:$50
Total Annual:$130
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$1,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$722
Comparison vs Placebo
Cost Difference
+$130/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Long-term Antiplatelet Therapy (Aspirin) Outcomes
for Ischemic Stroke
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+18%
Common Side Effects
Gastrointestinal bleeding
+1.5%
Dyspepsia
+5%
Sources:
Active Clinical Trials
1 active trial recruiting for Long-term Antiplatelet Therapy (Aspirin) in Ischemic Stroke
Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke
NCT06551727ENROLLING BY INVITATIONNA
70 participants
INTERVENTIONAL
Shanghai, China
Started: Aug 15, 2024
Completed Clinical Trials
2 completed trials for Long-term Antiplatelet Therapy (Aspirin) in Ischemic Stroke
Intensive Drug Therapy for Ischemic Stroke Caused by Severe Intracranial Arterial Stenosis
NCT05996978COMPLETED
42 participants
OBSERVATIONAL
Shanghai, China
Started: Feb 1, 2020
Enterprise Stent Implantation in the Treatment of Carotid Artery Stenosis With Ischemic Stroke
NCT02802072COMPLETEDNA
100 participants
INTERVENTIONAL
Started: Jan 1, 2013